NeuroBo Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2014-01-01
- Employees
- 8
- Market Cap
- -
- Website
- http://www.neurobopharma.com
- Introduction
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Cambridge, MA.
Clinical Trials
15
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (15 trials with phase data)• Click on a phase to view related trials
First in Human Study in Subjects With Obesity, But Otherwise Healthy
- First Posted Date
- 2024-02-09
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- NeuroBo Pharmaceuticals Inc.
- Target Recruit Count
- 81
- Registration Number
- NCT06252220
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH
- Conditions
- NON-ALCOHOLIC STEATOHEPATITIS
- Interventions
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- NeuroBo Pharmaceuticals Inc.
- Target Recruit Count
- 109
- Registration Number
- NCT06054815
- Locations
- 🇺🇸
Southern California Research Center, Coronado, California, United States
🇺🇸Catalina Research Institute, LLC, Montclair, California, United States
🇺🇸Velocity Clinical Research, Panorama City, Panorama City, California, United States
A Single and Multiple Ascending Dose Study of Niclosamide in Healthy Volunteers
- First Posted Date
- 2021-01-12
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- NeuroBo Pharmaceuticals Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT04705415
- Locations
- 🇺🇸
WCCT Global Inc., Cypress, California, United States
Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients
- First Posted Date
- 2020-10-27
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- NeuroBo Pharmaceuticals Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT04603924
- Locations
- 🇺🇸
Helen Keller Hospital, Sheffield, Alabama, United States
🇺🇸University of California, Irvine, Irvine, California, United States
🇺🇸Baptist Health Research Institute, Jacksonville, Florida, United States
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
- Conditions
- Severe HypertriglyceridemiaMixed Dyslipidaemia
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-10-25
- Last Posted Date
- 2020-06-25
- Lead Sponsor
- NeuroBo Pharmaceuticals Inc.
- Target Recruit Count
- 91
- Registration Number
- NCT02944383
- Locations
- 🇺🇸
Appalachian Research Associates, Fort Payne, Alabama, United States
🇺🇸Del Sol Research Mangagement, LLC, Tucson, Arizona, United States
🇺🇸Westside Medical Associates of Los Angeles, Beverly Hills, California, United States
- Prev
- 1
- 2
- 3
- Next